APO Research
Talk to an analyst

APO RESEARCH · REPORT

Allergy Immunotherapies

Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for some types of allergies. It is useful for environmental allergies, allergies to insect bites, and asthma. Its benefit for food allergies is unclear and thus not recommended. Immunotherapy involves exposing people to larger and larger amounts of allergen in an attempt to change the immune system's response.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for some types of allergies. It is useful for environmental allergies, allergies to insect bites, and asthma. Its benefit for food allergies is unclear and thus not recommended. Immunotherapy involves exposing people to larger and larger amounts of allergen in an attempt to change the immune system's response.

The primary therapeutic goals of allergy immunotherapy (AIT) include reducing symptoms, reducing symptomatic medication use, and improving allergyrelated quality of life. The evidence is strong that AIT achieves these goals and can alter the course of the disease, with benefits persisting in many patients for several years after treatment discontinuation.

Selected research

Market Outlook & Growth Opportunities

Global Allergy Immunotherapies Market Outlook and Growth Opportunities 2026

26 December 2025195 pages

Choose your research edition.

Industry ResearchAllergy Immunotherapies Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Allergy Immunotherapies Industry Growth and Trends Forecast to 203262 pages · $3,450 USDMarket StructureGlobal Allergy Immunotherapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Allergy Immunotherapies Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Allergy Immunotherapies Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for some types of allergies. It is useful for environmental allergies, allergies to insect bites, and asthma. Its benefit for food allergies is unclear and thus not recommended. Immunotherapy involves exposing people to larger and larger amounts of allergen in an attempt to change the immune system's response.

The primary therapeutic goals of allergy immunotherapy (AIT) include reducing symptoms, reducing symptomatic medication use, and improving allergyrelated quality of life. The evidence is strong that AIT achieves these goals and can alter the course of the disease, with benefits persisting in many patients for several years after treatment discontinuation.

In Southeast Asia Allergy Immunotherapies key players include ALK, Stallergenes, etc. Southeast Asia top two manufacturers hold a share about 65%.

Read the full market overview

Singapore is the largest market, with a share over 30%, followed by Thailand and Malaysia, both have a share about 35 percent.

In terms of product, Subcutaneous Immunotherapy is the largest segment, with a share about 43%. And in terms of application, the largest application is Allergic Rhinitis, followed by Allergic Asthma, etc.

This report provides an overview of the global Allergy Immunotherapies market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Allergy Immunotherapies and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Allergy Immunotherapies revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Allergy Immunotherapies market.

Allergy Immunotherapies Segment by Company

ALK

Stallergenes

HAL

Allergy Immunotherapies Segment by Type

Subcutaneous Immunotherapy

Sublingual Immunotherapy

Allergy Immunotherapies Segment by Application

Allergic Rhinitis

Allergic Asthma

Other

Allergy Immunotherapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Allergy Immunotherapies status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Allergy Immunotherapies key companies, revenue, market share, and recent developments.

3. To split the Allergy Immunotherapies breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Allergy Immunotherapies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Allergy Immunotherapies significant trends, drivers, influence factors in global and regions.

6. To analyze Allergy Immunotherapies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Allergy Immunotherapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Allergy Immunotherapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Allergy Immunotherapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Allergy Immunotherapies industry.

Chapter 3: Detailed analysis of Allergy Immunotherapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Allergy Immunotherapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Allergy Immunotherapies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Allergy Immunotherapies Industry Trends Table 2. Allergy Immunotherapies Industry Drivers Table 3. Allergy Immunotherapies Industry Opportunities and Challenges Table 4. Allergy Immunotherapies Industry Restraints Table 5. Global Allergy Immunotherapies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Allergy Immunotherapies Revenue Share by Company (2021-2026) Table 7. Global Allergy Immunotherapies Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Allergy Immunotherapies Key Company Manufacturing Base & Headquarters Table 9. Global Allergy Immunotherapies Company, Product Type & Application Table 10. Global Allergy Immunotherapies Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Allergy Immunotherapies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Subcutaneous Immunotherapy Table 15. Significant Companies of Sublingual Immunotherapy Table 16. Global Allergy Immunotherapies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Allergy Immunotherapies Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Allergy Immunotherapies Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Allergy Immunotherapies Sales Value Share by Type (2021-2026) Table 20. Global Allergy Immunotherapies Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Allergic Rhinitis Table 22. Significant Companies of Allergic Asthma Table 23. Significant Companies of Other Table 24. Global Allergy Immunotherapies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Allergy Immunotherapies Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Allergy Immunotherapies Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Allergy Immunotherapies Sales Value Share by Application (2021-2026) Table 28. Global Allergy Immunotherapies Sales Value Share by Application (2027-2032) Table 29. Global Allergy Immunotherapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Allergy Immunotherapies Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Allergy Immunotherapies Sales Value Share by Region (2021-2026) Table 32. Global Allergy Immunotherapies Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Allergy Immunotherapies Sales Value Share by Region (2027-2032) Table 34. Global Allergy Immunotherapies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Allergy Immunotherapies Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Allergy Immunotherapies Sales Value Market Share by Country (2021-2026) Table 37. Global Allergy Immunotherapies Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Allergy Immunotherapies Sales Value Market Share by Country (2027-2032) Table 39. ALK Company Information Table 40. ALK Business Overview Table 41. ALK Allergy Immunotherapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. ALK Allergy Immunotherapies Product Portfolio Table 43. ALK Recent Development Table 44. Stallergenes Company Information Table 45. Stallergenes Business Overview Table 46. Stallergenes Allergy Immunotherapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Stallergenes Allergy Immunotherapies Product Portfolio Table 48. Stallergenes Recent Development Table 49. HAL Company Information Table 50. HAL Business Overview Table 51. HAL Allergy Immunotherapies Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. HAL Allergy Immunotherapies Product Portfolio Table 53. HAL Recent Development Table 54. Research Programs/Design for This Report Table 55. Authors List of This Report Table 56. Secondary Sources Table 57. Primary Sources List of Figures Figure 1. Allergy Immunotherapies Product Image Figure 2. Global Allergy Immunotherapies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Allergy Immunotherapies Market Size (2021-2032) & (US$ Million) Figure 4. Global Allergy Immunotherapies Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Subcutaneous Immunotherapy Image Figure 8. Sublingual Immunotherapy Image Figure 9. Global Allergy Immunotherapies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Allergy Immunotherapies Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Allergy Immunotherapies Sales Value Share by Type (2021-2032) Figure 12. Allergic Rhinitis Image Figure 13. Allergic Asthma Image Figure 14. Other Image Figure 15. Global Allergy Immunotherapies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Allergy Immunotherapies Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Allergy Immunotherapies Sales Value Share by Application (2021-2032) Figure 18. Global Allergy Immunotherapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Allergy Immunotherapies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Allergy Immunotherapies Sales Value (2021-2032) & (US$ Million) Figure 21. North America Allergy Immunotherapies Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Allergy Immunotherapies Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Allergy Immunotherapies Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Allergy Immunotherapies Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Allergy Immunotherapies Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Allergy Immunotherapies Sales Value (2021-2032) & (US$ Million) Figure 27. South America Allergy Immunotherapies Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Allergy Immunotherapies Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Allergy Immunotherapies Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Allergy Immunotherapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous Immunotherapy
  • Sublingual Immunotherapy
Applications
  • Allergic Rhinitis
  • Allergic Asthma
  • Other
Companies covered
  • ALK
  • Stallergenes
  • HAL

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Allergy Immunotherapies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Allergy Immunotherapies Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Allergy Immunotherapies Market Dynamics
  1. 2.1 Allergy Immunotherapies Industry Trends
  2. 2.2 Allergy Immunotherapies Industry Drivers
  3. 2.3 Allergy Immunotherapies Industry Opportunities and Challenges
  4. 2.4 Allergy Immunotherapies Industry Restraints
3 Allergy Immunotherapies Market by Company
  1. 3.1 Global Allergy Immunotherapies Company Revenue Ranking in 2025
  2. 3.2 Global Allergy Immunotherapies Revenue by Company (2021-2026)
  3. 3.3 Global Allergy Immunotherapies Company Ranking (2024-2026)
  4. 3.4 Global Allergy Immunotherapies Company Manufacturing Base and Headquarters
  5. 3.5 Global Allergy Immunotherapies Company Product Type and Application
  6. 3.6 Global Allergy Immunotherapies Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Allergy Immunotherapies Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Allergy Immunotherapies Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Allergy Immunotherapies Market by Type
  1. 4.1 Allergy Immunotherapies Type Introduction
  2. 4.1.1 Subcutaneous Immunotherapy
  3. 4.1.2 Sublingual Immunotherapy
  4. 4.2 Global Allergy Immunotherapies Sales Value by Type
  5. 4.2.1 Global Allergy Immunotherapies Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Allergy Immunotherapies Sales Value by Type (2021-2032)
  7. 4.2.3 Global Allergy Immunotherapies Sales Value Share by Type (2021-2032)
5 Allergy Immunotherapies Market by Application
  1. 5.1 Allergy Immunotherapies Application Introduction
  2. 5.1.1 Allergic Rhinitis
  3. 5.1.2 Allergic Asthma
  4. 5.1.3 Other
  5. 5.2 Global Allergy Immunotherapies Sales Value by Application
  6. 5.2.1 Global Allergy Immunotherapies Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Allergy Immunotherapies Sales Value by Application (2021-2032)
  8. 5.2.3 Global Allergy Immunotherapies Sales Value Share by Application (2021-2032)
6 Allergy Immunotherapies Regional Value Analysis
  1. 6.1 Global Allergy Immunotherapies Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Allergy Immunotherapies Sales Value by Region (2021-2032)
  3. 6.2.1 Global Allergy Immunotherapies Sales Value by Region: 2021-2026
  4. 6.2.2 Global Allergy Immunotherapies Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Allergy Immunotherapies Sales Value (2021-2032)
  7. 6.3.2 North America Allergy Immunotherapies Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Allergy Immunotherapies Sales Value (2021-2032)
  10. 6.4.2 Europe Allergy Immunotherapies Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Allergy Immunotherapies Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Allergy Immunotherapies Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Allergy Immunotherapies Sales Value (2021-2032)
  16. 6.6.2 South America Allergy Immunotherapies Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Allergy Immunotherapies Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Allergy Immunotherapies Sales Value Share by Country, 2025 VS 2032
7 Allergy Immunotherapies Country-level Value Analysis
  1. 7.1 Global Allergy Immunotherapies Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Allergy Immunotherapies Sales Value by Country (2021-2032)
  3. 7.2.1 Global Allergy Immunotherapies Sales Value by Country (2021-2026)
  4. 7.2.2 Global Allergy Immunotherapies Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Allergy Immunotherapies Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Allergy Immunotherapies Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Allergy Immunotherapies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ALK
  2. 8.1.1 ALK Company Information
  3. 8.1.2 ALK Business Overview
  4. 8.1.3 ALK Allergy Immunotherapies Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ALK Allergy Immunotherapies Product Portfolio
  6. 8.1.5 ALK Recent Developments
  7. 8.2 Stallergenes
  8. 8.2.1 Stallergenes Company Information
  9. 8.2.2 Stallergenes Business Overview
  10. 8.2.3 Stallergenes Allergy Immunotherapies Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Stallergenes Allergy Immunotherapies Product Portfolio
  12. 8.2.5 Stallergenes Recent Developments
  13. 8.3 HAL
  14. 8.3.1 HAL Company Information
  15. 8.3.2 HAL Business Overview
  16. 8.3.3 HAL Allergy Immunotherapies Revenue and Gross Margin (2021-2026)
  17. 8.3.4 HAL Allergy Immunotherapies Product Portfolio
  18. 8.3.5 HAL Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst